Arvinas (ARVN) Q3 2024 earnings summary

Executive summary

• Awaiting pivotal phase III data readout for vepdeg/vepdegestrant in ER-positive, HER2-negative breast cancer by end of 2024 or Q1 2025, marking a major transition toward commercial stage status.

• Pipeline includes PROTAC degraders for oncology and neuroscience, with ongoing trials in breast cancer, neurodegenerative diseases, and B-cell lymphomas.

• Strategic collaborations with Pfizer (vepdeg) and Novartis (ARV-766) support development and commercialization efforts.

• Revenue rose significantly year-over-year, driven by a new Novartis license and asset agreement for ARV-766, offsetting declines in other collaborations.

• Net loss narrowed both for the quarter and year-to-date, reflecting higher revenue and lower R&D costs.

Financial highlights

• Q3 2024 revenue was $102.4 million, up from $34.6 million in Q3 2023, mainly due to $76.7 million from the Novartis license agreement.

• Net loss for Q3 2024 was $49.2 million, improved from $64.0 million in Q3 2023.

• General and administrative expenses rose to $75.8 million, primarily due to a $43.4 million lease termination and increased personnel costs.

• R&D expenses were $86.9 million, up $1 million year-over-year, reflecting higher personnel costs.

• Cash, cash equivalents, and marketable securities totaled $1.12 billion at quarter-end, sufficient to fund operations into 2027.

Outlook and guidance

• Top-line phase III data for vepdeg/vepdegestrant expected by end of 2024 or Q1 2025; positive results could lead to first NDA filing and commercial launch.

• Anticipates starting two additional phase III programs for vepdeg in 2025, pending regulatory feedback.

• Initial data from ARV-102 phase I trial in neurodegenerative diseases expected in 2025.

• Preparing to file IND for KRAS G12D program in 2025.

• Cash reserves expected to fund planned operations and capital expenditures into 2027.